Swire Pacific B (00087) spent 1.86 million Hong Kong dollars on repurchasing 187,500 shares on September 20th.
The announcement was made by TAIGU Holdings Company B (00087) on September 20, 2024, stating that the company had invested 186.08...
SWIRE PACIFIC B (00087) announced that the company has repurchased 187,500 shares at a total cost of HK$1.8608 million on September 20, 2024, with a repurchase price ranging from HK$9.76 to HK$9.97 per share.
Related Articles
HENLIUS (02696)The clinical trial application for the treatment of advanced squamous non-small cell lung cancer with PIMURUTAMAB HLX07 in combination with Hanxiuzhuang and chemotherapy has been approved by the National Medical Products Administration.
Beijing Foyou Pharma (601089.SH): The clinical trial of FY103 injection has been approved. Currently, there are no similar products with the same target on the market both domestically and internationally.
Beijing Foyou Pharma (601089.SH): Sodium diclofenac enteric-coated capsules received drug registration certificate.
HENLIUS (02696)The clinical trial application for the treatment of advanced squamous non-small cell lung cancer with PIMURUTAMAB HLX07 in combination with Hanxiuzhuang and chemotherapy has been approved by the National Medical Products Administration.
Beijing Foyou Pharma (601089.SH): The clinical trial of FY103 injection has been approved. Currently, there are no similar products with the same target on the market both domestically and internationally.
Beijing Foyou Pharma (601089.SH): Sodium diclofenac enteric-coated capsules received drug registration certificate.
